Atlas Trials

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine

Clinical trial NCT04880785 · COMPLETED

Trial details

NCT number
NCT04880785
Sponsor
Fundacion SEIMC-GESIDA
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HIV Infections
Start date
2021-07-28
Primary completion
2023-06-12
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.